日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial

一线治疗EGFR突变型非小细胞肺癌患者,比较奥莫替尼(EGFR酪氨酸激酶抑制剂)联合阿帕替尼(VEGFR抑制剂)与奥莫替尼单药治疗的疗效:一项随机、多中心、II期临床试验

Zhang, Fan; Zheng, Zhendong; Zhang, Hongmei; Yan, Xiaolong; Liu, Zhefeng; Yang, Fan; Wen, Juyi; Gan, Xin; Wu, Lin; Cang, Shundong; Wang, Hongmei; Zhao, Jun; Peng, Liang; Li, Xiaosong; Fan, Zaiwen; Shen, Ge; Zhou, Qiong; Zou, Jinjing; Xu, Yu; Zhang, Lei; Zhao, Mingfang; Cai, Shangli; Hu, Yi

Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study

瑞维替尼治疗伴有中枢神经系统转移的EGFR突变型非小细胞肺癌患者:来自III期REZOR研究的中枢神经系统疗效

Yang, Sheng; Zhao, Yanqiu; Sun, Meili; Bi, Minghong; Zhu, Bo; Chen, Zhaohong; Yu, Huiqing; Zhang, Liangming; Wu, Lin; Zhou, Rui; Yao, Wenxiu; Li, Xingya; Han, Zhigang; Wang, Ke; Wang, Lijun; Wen, Meiling; Guo, Yanzhen; Lin, Yingcheng; Sun, Shenghua; Guo, Shuliang; Yi, Tienan; Zhao, Wenhua; Yu, Zhuang; Qin, Jianwen; Pan, Yueyin; He, Zhiyong; Ye, Feng; Shi, Huaqiu; Fang, Jian; Ma, Rui; Lu, Hong; Zhang, Hua; Shi, Jianhua; Gao, Jinghua; Cui, Jiuwei; Li, Manxiang; Yi, Shanyong; Cang, Shundong; Shu, Yongqian; Zhang, Don; Peng, Jirong; Gao, Feng; Wang, Tingting; Zhou, Anqi; Shi, Yuankai

Prognostic impact of regional lymph node excision in T3-4N+M0 gastric cancer: a retrospective cohort study on nomogram development and external validation in China

区域淋巴结切除对T3-4N+M0期胃癌预后的影响:一项在中国开展的回顾性队列研究,旨在构建预测模型并进行外部验证

Li, Kexun; Leng, Xuefeng; He, Wenwu; Du, Kunyi; Li, Changding; Liu, Kun; Wang, Chenghao; Liu, Guangyuan; Li, Zhiyu; Jiang, Longlin; Li, KunZhi; Zhou, Qiang; Li, Jialong; Luo, Xi; Nie, Xin; Lu, Simiao; Li, Haojun; Fang, Qiang; Xiao, Wenguang; Han, Yongtao; Peng, Lin; Gao, Xuejin; Zhang, Yupeng; Xiao, Yaqin; Gao, Tingting; Jin, Gang; Wang, Kunhua; Zhou, Yanbing; Chi, Qiang; Yang, Hua; Li, Mengbin; Yu, Jianchun; Qin, Huanlong; Tang, Yun; Wu, Xiaoting; Li, Guoli; Zhang, Li; Wang, Xinying; Tian, Chenrui; Sun, Aiping; Yu, Haodi; Song, Guozhen; Wang, Yongbin; Zhang, Qingyu; Cang, Shundong

Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial

HA121-28 在晚期实体瘤和 RET 融合阳性非小细胞肺癌患者中的安全性、药代动力学和疗效:一项多中心、开放标签、单臂 1/2 期试验

Ruan, Dan-Yun; Huang, Wen-Wen; Li, Yongsheng; Zhao, Yanqiu; Shi, Yehui; Jia, Yuming; Cang, Shundong; Zhang, Wei; Shi, Jianhua; Chen, Jun; Lin, Jie; Liu, Yunpeng; Xu, Jianming; Ouyang, Weiwei; Fang, Jian; Zhuang, Wu; Liu, Caigang; Bu, Qing; Li, Manxiang; Meng, Xiangjiao; Sun, Meili; Yang, Nong; Dong, Xiaorong; Pan, Yueyin; Li, Xingya; Qu, Xiujuan; Zhang, Tongmei; Yuan, Xianglin; Hu, Sheng; Guo, Wei; Li, Yalun; Li, Shengqing; Liu, Dongying; Song, Feixue; Tan, Liping; Yu, Yan; Yu, Xinmin; Zang, Aimin; Sun, Chang; Zhang, Qian; Zou, Kai; Dan, Mo; Xu, Rui-Hua; Zhao, Hongyun

A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib

一项前瞻性、多中心、全面的基因组特征研究,针对一线奥希替尼治疗失败的EGFR突变晚期非小细胞肺癌患者。

Shi, Yuankai; Lv, Dongqing; Feng, Weineng; Liu, Shuoyan; Xing, Puyuan; Yu, Yan; Yin, Jun; Ren, Xiubao; Zhang, Junqiang; Han, Gaohua; Zhang, Yongchang; Cang, Shundong; Chen, Jun; Chen, Enguo; Meng, Lingxin; Zhang, Yong

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)

一项针对接受 EGFR-TKI 治疗后出现渐进性、寡转移性或潜在进展的晚期非小细胞肺癌患者的 II 期试验,评估安罗替尼联合 EGFR-TKI 的疗效 (CTONG-1803/ALTER-L001)

Chen, Hua-Jun; Tu, Hai-Yan; Hu, Yanping; Fan, Yun; Wu, Guowu; Cang, Shundong; Yang, Yi; Yang, Nong; Ma, Rui; Jin, Gaowa; Xu, Ximing; Liu, Anwen; Tang, Shubin; Cheng, Ying; Yu, Yan; Xu, Chong-Rui; Zhou, Qing; Wu, Yi-Long

The lncRNA PARylator promotes PARP1 activation and resistance to DNA‑damaging therapy in esophageal squamous cell carcinoma

lncRNA PARylator促进PARP1激活和食管鳞状细胞癌对DNA损伤疗法的耐药性

Qi, Teng Fei; Liu, Yadong; Yang, Jinkun; Yue, Yi Meng; Han, Man Man; Liu, Hongtao; Li, Jing; Liu, Min; Zhang, Yuwei; Kou, Jia Hui; Li, Wen Jin; Liu, Xiaoying; La, Ting; Liu, Tao; Chen, Song; Zhang, Xu Dong; Cang, Shundong; Teng, Liu; Fan, Tianli

OTUD7B is a new deubiquitinase targeting p53.

OTUD7B 是一种靶向 p53 的新型去泛素化酶

Ding Caoyuan, Cao Leixi, Wang Ruijie, Wu Qichen, Li Mengfan, Zhang Jinjing, Thorne Rick F, Li Jinming, Ma Jianli, Wu Mian, Cang Shundong

Telpegfilgrastim for chemotherapy-induced neutropenia in breast cancer: A multicenter, randomized, phase 3 study

Telpegfilgrastim治疗乳腺癌化疗引起的粒细胞减少症:一项多中心、随机、3期研究

Shi, Yuankai; Zhang, Qingyuan; Wang, Junsheng; Ouyang, Zhong; Yi, Tienan; Mei, Jiazhuan; Wang, Xinshuai; Pei, Zhidong; Sun, Tao; Bai, Junheng; Cang, Shundong; Li, Yarong; Fu, Guohong; Ma, Tianjiang; Shi, Huaqiu; Liu, Jinping; Wang, Xiaojia; Niu, Hongrui; Guo, Yanzhen; Zhou, Shengyu; Sun, Li

BRAP Promotes the Tumorigenesis of Hepatocellular Carcinoma by Corrupting Cancer Cell Cycle Regulation and Enhancing Immune Evasion.

BRAP 通过破坏癌细胞周期调控和增强免疫逃逸来促进肝细胞癌的肿瘤发生。

Guo Yan, Gu Ruixue, Gao Fangmiao, Liu Lina, Deng Dongfeng, Zhang Qinyu, Wang Longhao, Liu Qinglin, Lan Ling, Cang Shundong